Opinion · 1 Dec 2025
Brief reportPublished 30 Nov 2024
Global Trends in Neuro Psycho Pharmacological Prescriptions for Adults with Schizophrenia: Clinical Correlates and Practice Implications
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The treatment of schizophrenia has evolved significantly over the years, with neuropsychopharmacological interventions remaining central to symptom management and improving patient outcomes. Schizophrenia, a complex and chronic psychiatric disorder, affects millions of individuals worldwide, posing significant challenges for healthcare systems, patients, and caregivers alike. The condition is characterized by symptoms such as delusions, hallucinations, disorganized thinking, and impaired cognitive functioning, necessitating a multifaceted therapeutic approach. This scoping review examines global trends in the prescription of neuropsychopharmacological agents for adults with schizophrenia, explores associated clinical correlates, and discusses the implications for clinical practice. Across the globe, antipsychotic medications serve as the cornerstone of schizophrenia treatment. These drugs are broadly categorized into two classes: typical (first-generation) and atypical (secondgeneration) antipsychotics.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Pharmacoeconomics: Open Access.
Short communication · 1 Dec 2025
Preventive Drugs for Older Adults: Health and Economic Benefits
Brief report · 29 Nov 2025
Value Assessment Of High-cost Specialty Drugs
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmacoeconomics: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Helen Panattoni”
